References

  1. Orgiazzi J. Traitement de la maladie de Basedow;problématiques actuelles. Presse Med. 2011;40(12):1155-62. PubMed | Google Scholar

  2. Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves´ disease. J Clin Endocrinol Metab. 2012;97(12):4549-58. PubMed | Google Scholar

  3. Sundaresh V, Brito JP, Thapa P, Bahn RS, Stan MN. Comparative Effectiveness of Treatment Choices for Graves´ Hyperthyroidism;A Historical Cohort Study. Thyroid. 2017;27(4):497-505. PubMed | Google Scholar

  4. Corvilain B, Hamy A, Brunaud L, Borson-Chazot F, Orgiazzi J, Bensalem Hachmi L et al. Treatment of adult Graves' disease. Ann Endocrinol (Paris). 2018;79(6):618-635. PubMed | Google Scholar

  5. Yamashita Y, Yamane K, Tamura T, Okubo M, Kohno N. Onset Age is Associated with Outcome of Radioiodine Therapy in Graves´ disease. Endoc J. 2004;51(2):127-32. PubMed | Google Scholar

  6. Plazinska MT, Sawicka-Gutaj N, Czarnywojtek A, Wolinski K, Kobylecka M, Karlińska M et al. Radioiodine therapy and Graves' disease-Myths and reality. 2020 Jan 13;15(1):e0226495. PubMed | Google Scholar

  7. Kinuya S, Michigishi T, Nakajima K, Kinuya K, Seto A, Kuji I et al. Failure of radioiodine treatment in Graves´ disease intentionally caused by a patient: Suspected Munchausen syndrome. Ann Nucl Med. 2004;18(7):631-2. PubMed | Google Scholar

  8. Hegedüs L, Bonnema SJ. Calculating the incalculable, Optimal radioiodine dose in Graves' hyperthyroidism. Endocrine. 2017;56(1):222-223. PubMed | Google Scholar

  9. Hammes J, van Heek L, Hohberg M, Reifegerst M, Stockter S, Dietlein M et al. Impact of different approaches to calculation of treatment activities on achieved doses in radioiodine therapy of benign thyroid diseases. EJNMMI Phys. 2018 12;5(1):32. PubMed | Google Scholar

  10. Yau JS, Chu KS, Li JK, Chan KW, Lau IT, Yum SW et al. Usage of a fixed dose of radioactive iodine for the treatment of hyperthyroidism;one-year outcome in a regional hospital in Hong Kong. Hong Kong Med J. 2009;15(4):267-73. PubMed | Google Scholar

  11. Burch HB, Cooper DS. Management of Graves Disease A Review. JAMA. 2015;314(23):2544-54. PubMed | Google Scholar

  12. Collier A, Ghosh S, Hair M, Malik I, McGarvie J. Comparison of two fixed activities of radioiodine therapy (370 vs 555 MBq) in patients with Graves´ disease. Hormones (Athens). 2009;8(4):273-8. PubMed | Google Scholar

  13. Sapienza MT, Coura-Filho GB, Willegaignon J, Watanabe T, Duarte PS, Buchpiguel CA. Clinical and Dosimetric Variables Related to Outcome After Treatment of Graves' Disease With 550 and 1110 MBq of 131I;Results of a Prospective Randomized Trial. Clin Nucl Med. 2015;40(9):715-9. PubMed | Google Scholar

  14. Abraham P, Acharya S. Current and emerging treatment options for Graves´hyperthyroidism. Ther Clin Risk Manag. 2010;6:29-40. PubMed | Google Scholar

  15. Girgis CM, Champion BL, Wall JR. Current concepts in Graves´ disease. Ther Adv Endocrinol Metab. 2011;2(3):135-44. PubMed | Google Scholar

  16. Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad M et al. Comparative Effectiveness of Therapies for Graves´ Hyperthyroidism: A Systematic Review and Network Meta-Analysis. J Clin Endocrinol Metab. 2013;98(9):3671-7. PubMed | Google Scholar

  17. Brito JP, Payne S, Singh-Ospina N, Rodriguez-Gutierrez R, Maraka S, Sangaralingham L et al. Patterns of use, efficacy and safety of treatment options for patients with Graves' disease: A Nationwide Population-Based Study. Thyroid. 2020 Jan 23. PubMed | Google Scholar

  18. Yang D, Xue J, Ma W, Liu F, Fan Y, Rong J, Yang A, Yu Y. Prognostic factor analysis in 325 patients with Graves' disease treated with radioiodine therapy.Nucl Med Commun. 2018;39(1):16-21. PubMed | Google Scholar

  19. Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves´ hyperthyroidism: one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab. 2001;86(8):3488-93. PubMed | Google Scholar

  20. Ogunjobi KO, Ejeh JE, Adedapo KS, Eniojukan JF. Effectiveness of fixed dose radioactive iodine (RAI) for the treatment of hyperthyroidism;experience of a teaching hospital in South West Nigeria. Mol Imaging Radionucl Ther. 2013;22(2):36-41. PubMed | Google Scholar

  21. Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS et al. Effects of antithyroid drugs on radioiodine treatment;systematic review and meta-analysis of randomised controlled trials. Br Med J. 2007;334(7592):514. PubMed | Google Scholar

  22. Ponto KA, Zang S, Kahaly GJ. The tale of radioiodine and Graves' orbitopathy. Thyroid. 2010 Jul;20(7):785-93. PubMed | Google Scholar

  23. Eha J, Pitz S, Pohlenz J. Clinical features of pediatric Graves´ orbitopathy. Int ophthalmol. 2010;30(6):717-21. PubMed | Google Scholar

  24. Krassas GE, Segni M, Wiersinga WM. Childhood Graves´ ophthalmopathy: results of a European questionnaire study. Eur J Endocrinol. 2005;153(4):515-21. PubMed | Google Scholar

  25. Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P. Radioiodine therapy (RAI) for Graves´ disease (GD) and the effect on ophthalmopathy: a systematic review. Clini Endocrinol (oxf). 2008;69(6):943-950. PubMed | Google Scholar

  26. Rasmussen AK, Nygaard B, Feldt-Rasmussen U. (131) I and thyroid-associated ophthalmopathy. Eur J Endocrinol. 2000;143(2):155-60. PubMed | Google Scholar

  27. Vannucchi G, Covelli D, Campi I, Currò N, Dazzi D, Rodari M. Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation, A Prospective Randomized Control Trial Study. Thyroid. 2019 Dec;29(12):1828-1833. PubMed | Google Scholar

  28. Howarth D, Epstein M, Lan L, Tan P, Booker J. Determination of the optimal minimum radioiodine dose in patients with Graves´ disease;a clinical outcome study. Eur J Nucl Med Mol Imaging. 2001;28(10):1489-95. PubMed | Google Scholar

  29. Vija Racaru L, Fontan C, Bauriaud-Mallet M, Brillouet S, Caselles O, Zerdoud S et al. Clinical outcomes 1 year after empiric 131I therapy for hyperthyroid disorders: real life experience and predictive factors of functional response. Nucl Med Commun. 2017;38(9):756-63. PubMed | Google Scholar

  30. Iagaru A, McDougall IR. Treatment of Thyrotoxicosis. J Nucl Med. 2007;48(3):379-89. PubMed | Google Scholar

  31. Hernndez-Jimenez S, Pachon-Burgos A lvaro, Aguilar-Salinas CA, Andrade V, Reynoso R, Rios A et al. Radioiodine Treatment in Autoimmune Hyperthyroidism: Analysis of Outcomes in Relation to Dosage. Med Res Arch. 2007;38(2):190-5. PubMed | Google Scholar

  32. Husseni MAEKES. The Incidence of Hypothyroidism Following the Radioactive Iodine Treatment of Graves´ Disease and the Predictive Factors Influencing its Development. World J Nucl Med. 2016;15(1):30-7. PubMed | Google Scholar

  33. Santos RB, Romaldini JH, Ward LS. A randomized controlled trial to evaluate the effectiveness of 2 regimens of fixed iodine (131I) doses for Graves disease treatment. Clin Nucl Med. 2012;37(3):241-4. PubMed | Google Scholar

  34. Jiehua XU, Zhang Z, Cheng M, Ping W, Chunxing WU, Hong S. Influencing factors of radioiodine therapy in hyperthyroidism in adults. Nucl Sci Tech. 2007;18(5):294-7. PubMed | Google Scholar

  35. Isgoren S, Gorur GD, Demir H, Berk F. Radioiodine therapy in Graves ´ disease: Is it possible to predict outcome before therapy? Nucl Med Commun. 2012;33(8):859-63. PubMed | Google Scholar

  36. Sarkar SD. Benign thyroid disease: what is the role of nuclear medicine? Semin Nucl Med. 2006;36(3):185-93. PubMed | Google Scholar

  37. Shah KK, Tarasova V, Davidian M, Anderson RJ. Painful acute radiation thyroiditis induced by 131I treatment of Graves´ disease. BMJ Case Rep. 2015;bcr2014207670. PubMed | Google Scholar

  38. Bobanga ID, McHenry CR. Treatment of patients with Graves' disease and the appropriate extent of thyroidectomy. Best Pract Res Clin Endocrinol Metab. 2019;33(4):101319. PubMed | Google Scholar

  39. Smithson M, Asban A, Miller J, Chen H. Considerations for Thyroidectomy as Treatment for Graves Disease. Clin Med Insights Endocrinol Diabetes. 2019 Apr 24;12:1-5. PubMed | Google Scholar